RxDoctor Payments Data

Edward Oldfield, MD

Gastroenterology · Norfolk, VANPI 1376938530

Payments from drug & device makers

$25,938in general payments, 2019–2025

Across 120 payments — averaging $216.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$18K
  • Celltrion USA Inc.$4K
  • Olympus Corporation Of The Americas$3K
  • AbbVie$469
  • Takeda Pharmaceuticals U.S.A., Inc.$195
  • Bristol Myers Squibb$126
  • plus $541 from 12 others

What the payments were for

  • Consulting fees$1,1805%
  • Speaking & faculty fees$18,74472%
  • Travel & lodging$3,95615%
  • Food & beverage$2,0358%
  • Education$230%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,938 in reported general payments places this provider in the 85th percentile of 473 gastroenterology providers in Virginia.

See all gastroenterology providers in Virginia

Medicare billing

Part B allowed, 2024
$177,166
Medicare patients
564
Services billed
951

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab48$1,245,852
Humira(Cf) PenAdalimumab24$292,975
EntyvioVedolizumab21$181,293
CreonLipase/Protease/Amylase20$73,447
ZenpepLipase/Protease/Amylase18$35,011
LinzessLinaclotide49$33,727
VemlidyTenofovir Alafenamide11$16,175
Mesalamine17$8,795
MotegrityPrucalopride Succinate15$7,658
Dexlansoprazole DrDexlansoprazole23$5,166
Ursodiol16$4,957
Tenofovir Disoproxil Fumarate20$3,008
Omeprazole209$2,831
Esomeprazole Magnesium18$855
Pantoprazole Sodium43$804

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$17,861$1,245,85248 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio, Motegrity$195$188,95136 claims
AbbVieCreon, Linzess$469$107,17569 claims
GileadVemlidy$104$16,17511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 473 gastroenterology providers in Virginia.

Other gastroenterology in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →